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(0.42% vs. 0.79%) reduction in rates of AAA-related mortality and rupture, respec-
tively, as compared to the standard ultrasound strategy. During an 8-year follow-up 
period, the higher cost of elective surgeries by the PSU strategy was partially offset by 
lower rates and costs of emergency surgeries compared to the standard ultrasound 
strategy. The higher screening rate with the PSU strategy resulted in a cost savings of 
c17 per screened eligible male over 8 years (annualized c2/year). Sensitivity analyses 
demonstrated reductions in deaths and aortic ruptures ranging from 17% to 50% and 
2% to 73%, respectively, at a maximum cost-savings of c7 to c50, and only one 
instance of an incremental cost of c3 per eligible patient over 8 years. CONCLU-
SIONS: Use of a PSU device to screen for AAA may reduce deaths, aortic ruptures, 
and surgery costs with a savings of c2/year per screened eligible male.
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OBJECTIVES: Patients hospitalized for Heart Failure (HF) continue to have high 
re-admission and mortality rates in the 30 days following discharge. Cardiac param-
eters such as left ventricular function (LVF) and inferior vena cava (IVC) size are 
predictors of mortality and readmission, and are presently assessed by 2-dimensional 
echocardiography (2DE). Pocket-sized ultrasound (PSU) devices for LVF and IVC 
assessment offer potential advantages of lower cost, increased availability, and porta-
bility as compared to 2DE. The study objective was to develop a model to assess the 
clinical and economic impact of PSU versus 2DE for HF hospitalizations in Italy. 
METHODS: The model was developed from an Italian hospital perspective, and 
timeframe was during HF hospitalization to 30 days post-discharge. The clinical 
scenario evaluated the impact of LVF assessment on mortality, while the economic 
scenario incorporated the impact of IVC size on costs (2010 Euros). Our model 
assumed 100% of PSU patients would undergo evaluation, as compared to only 68% 
who currently undergo 2DE. We assumed abnormalities identiﬁ ed by PSU would 
require subsequent 2DE evaluation while lack of abnormalities would not require 
2DE. Model outputs of number of deaths, readmissions, and costs were calculated 
using a sample of 186,000 HF hospitalizations. One-way sensitivity analyses were 
conducted to evaluate the robustness of model outcomes. RESULTS: A PSU strategy 
yielded a 19.1% (7.2% vs. 8.1%) reduction in the 30-day mortality rate, as compared 
to the 2DE strategy, and a 33.4% (26.0% vs. 39.1%) reduction in 30-day readmis-
sions leading to a cost savings of c55 million (c297/ HF admission). Models were 
robust to changes in model inputs with reduction in deaths from 2–37%, and cost 
savings from c63–315 per HF admission. CONCLUSIONS: Use of a PSU device to 
visualize key cardiac parameters for HF hospitalizations in Italy may afford reduction 
in deaths and cost-savings.
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OBJECTIVES: To assess and compare direct in-hospital costs in patients hospitalized 
with acute coronary syndromes (ACS; unstable angina or myocardial infarction), acute 
heart failure (AHF) and acute coronary syndromes complicated by heart failure (ACS 
with AHF) from health care payer perspective. METHODS: Patients hospitalized from 
2005 to 2008 were classiﬁ ed in registry of Faculty Hospital Brno according to the 
clinical characteristics. Direct in-hospital costs (ﬂ at rate of admission and stay; medica-
tion and procedures) were evaluated in total 965 ACS (73% male; 64.7 years; 54% 
STEMI), 962 AHF (56% male; 70.8 years) and 808 AHF with ACS (62% male; 71.2 
years; 61% STEMI) patients. The severity of disease was qualiﬁ ed as need of intensive 
care (ICU days); the predictors of high cost were identiﬁ ed in all groups. (1c = 26CZK). 
RESULTS: Mean in-hospital cost was 101658CZK/3910c in ACS pts (length-of-stay 
5.6 days; 81% pts 2.3 ICU days; 0.3% died), 70201CZK/2700c in AHF pts (length-
of-stay 9 days; 48 % pts 4 ICU days; 11.4 % died) and 122340CZK/4705c in ACS 
with AHF (length-of-stay 7.2 days; 92% pts 3.5 ICU days; 19.2% died). Percutaneous 
coronary intervention with stenting (PCI) formed more than 80% of total cost in ACS 
patients (performed in 78% pts.; 91% STEMI; 62% non-STEMI) and almost 60% 
costs in ACS with AHF pts (performed in 66% pts; 84% STEMI; 39% non-STEMI); 
antiarrhythmic interventions (incl. ICD, CRT BiV or PM device) made almost 50% 
cost in AHF although carried out in 8.6% pts. CONCLUSIONS: According to in-
hospital costs patients with acute coronary syndromes complicated by heart failure 
were the most costly with maximum need of intensive care. Since 26.7% pts were 
transferred to other health care institution (e.g. 9% cardiosurgery) we expect the most 
signiﬁ cant increase of total amount of direct in-hospital costs in comparison with ACS 
(16.9% pts transferred) or AHF (11.5% pts transferred).
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OBJECTIVES: The TRITON-TIMI 38 Trial demonstrated that in patients with acute 
coronary syndromes (ACS) undergoing planned percutaneous coronary intervention 
(PCI), prasugrel compared to clopidogrel signiﬁ cantly reduced the rate of ischemic 
events over up to 15 months of follow-up, though there was an increased risk of major 
bleeding. Three risk factors for bleeding identiﬁ ed in the trial were a prior history of 
stroke/TIA, age ≥75 years, and body weight <60 kg. Patient-level data from TRITON 
was used to compare hospitalization costs in South Korea for patients without these 
risk factors for bleeding, who were randomized to prasugrel vs. clopidogrel. 
METHODS: Details regarding hospitalizations for all patients from 8 high enrolling 
countries (US, Australia, Canada, Germany, Italy, Spain, UK, France; n = 3373 pra-
sugrel, 3332 clopidogrel) were collected prospectively. The US diagnosis-related group 
codes were assigned to all hospitalizations, to which 2009 South Korean unit costs 
were applied. Estimates of incremental costs associated with PCI-associated peripro-
cedural MIs and PCI- and CABG-associated bleeding events were added separately, 
based on published U.S. data. RESULTS: Prasugrel was associated with a 17,723 
KRW per patient increase in costs due to bleeding, and an 8,377 KRW decrease in 
costs due to reduced periprocedural MI, during the index hospitalization. Per-patient 
costs from hospitalization for MI (not involving revascularization) during the follow-
up period were 291,022 KRW lower with prasugrel compared to clopidogrel, and 
costs associated with revascularization hospitalizations during follow-up were 
505,032 KRW lower. Costs from follow-up bleeding events were 52,082 KRW higher 
for prasugrel, while aggregate hospitalization costs were 293,656 KRW lower. CON-
CLUSIONS: For ACS patients with planned PCI, the lower ischemic event rate with 
prasugrel yields a reduction in overall hospitalization costs, despite increased costs 
from bleeding. These results have implications for the cost-effectiveness of alternative 
antiplatelet strategies for ACS patients undergoing PCI in South Korea.
PCV43
OFFSETTING ANNNUAL CARDIOVASCULAR DISEASE-RELATED 
MEDICAL AND PHARMACY COSTS BETWEEN PATIENTS CONTINUING 
STATIN MONOTHERAPY OR AUGMENTING STATIN MONOTHERAPY 
WITH NIACIN EXTENDED-RELEASE
Quimbo RA1, Simko RJ2, Cziraky MJ1, Webb S2
1HealthCore, Wilmington, DE, USA; 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To compare cardiovascular disease (CVD) associated costs between 
patients continuing statin (simvastatin 20 mg/day or equivalent) monotherapy (SM) 
or receiving adjunct therapy with niacin extended-release (NER) for comprehensive 
lipid management. METHODS: Secondary risk patients age ≥30 continuing SM or 
augmenting statin therapy with NER between January 1, 2005-November 30, 2008 
(index date) with ≥1 pre-index lipid panel (LDL-C < 100 mg/dL & HDL-C < 50 or 
<55 mg/dL for men & women, respectively) and no hepatic dysfunction were included. 
SM patients were matched 3:1 to NER patients based on prior exposure to statin. The 
primary outcome was total (medical and pharmacy) annual CVD-related costs. 
Medical and pharmacy costs consisted of inpatient, emergency room, and outpatient 
expenditures associated with CVD and pharmacy charges for anti-hyperlipidemic 
therapy. Outcome comparison between SM and NER and was conducted via general-
ized linear models via gamma distribution and log-link function. Multivariate analyses 
controlled for age, gender, geography, co-morbidities, and baseline lipids. RESULTS: 
A total of 728 patients were identiﬁ ed; 546 SM patients were matched to 182 NER 
patients. Compared to SM, there was no difference in baseline LDL-C (P = 0.13) or 
Deyo-Charlson co-morbidity Index scores (P = 0.77). Baseline HDL-C (35 ± 6 vs. 42 
± 7; P < 0.0001) was lower and TG (190 ± 98 vs. 153 ± 76; P < 0.0001) was higher 
among NER patients. While annual CVD-related pharmacy expenditure was higher 
for NER [mean (95% CI), $2261 ($1991–$2587) vs. $1276 ($1186–$1373)], adjusted 
and unadjusted medical costs were 69% (P = 0.0002) lower for NER ($542 ($378–
$799) vs. $1718 ($1373–$2149); P < 0.0001) vs. SM. Offsets in medical and pharmacy 
costs resulted in total annual CVD-related costs between NER and SM (($2796 
($2331–$3353) vs. $2988 ($2960–$3318); P = 0.5346). CONCLUSIONS: Therapy 
augmentation with NER for comprehensive lipid management was associated with 
reduced annual CVD-related medical expenditure leading to total annual CVD-related 
costs compared to statin monotherapy.
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OBJECTIVES: Compare the risk of subsequent coronary event (SCE), cerebrovascular 
event, and associated medical costs between patients maintaining statin monotherapy 
(SM) or augmenting statin with fenoﬁ brate (FF) after an acute coronary event (ACE). 
